<b>Early and Late Outcome of Stenting in a Consecutive Series of Patients With Coronary Lesions in Vessels Less Than 2.8 mm in Diameter</b>

Abstract

SUMMARYIn an attempt to determine the early and late outcomes of small vessel stenting, we retrospectively evaluated our database on 51 consecutive patients (41 males, mean age, 57.1 ± 10.1 years) who underwent stenting of at least one significant lesion in a coronary artery with a reference vessel diameter (RVD) < 2.8 mm between March 1999 and March 2001.Sixty balloon expandable tubular stents were implanted in 57 lesions (29 Type B2/C, mean RVD: 2.54 ± 0.16 mm) without intravascular ultrasound guidance under a heparinaspirin-ticlopidine regimen. The mean diameter stenosis (DS) decreased from 75.8 ± 13.6% to 4.2 ± 1.9% (P < 0.0001) with stenting at a mean deployment pressure of 13.6 ± 1.7 atm and a final balloon to RVD ratio (FB/RVD) of 1.08 ± 0.03. All stents were deployed successfully. Acute stent thrombosis occurred in 3 patients (6%), one died, and 2 developed non-Q-wave myocardial infarction (procedural success 94%). Clinical follow-up, available in 48 patients, revealed a 29% target lesion revascularization rate, a 2% myocardial infarction rate, and a 71% event-free survival at a mean of 11.6 months. Angiographic follow-up, available in 40 patients, showed a DS of 48.8 ± 31.3% and a binary restenosis rate of 50% at a mean of 7.7 months. The FB/RVD ratio was significantly lower in the group with restenosis than in the group without (1.06 ± 0.02 vs 1.1± 0.05, P = 0.04). Subgroup analysis yielded a significantly greater rate of restenosis in diabetics with complex (Type B2/C) lesion morphology compared to nondiabetics with simple (Type A/B1) lesions (75% vs 21%, P < 0.05).In conclusion, stenting in vessels < 2.8 mm was found to be associated with a high rate of acute stent thrombosis and in-stent restenosis. Further analysis detected a subgroup of patients without diabetes or complex lesions who could be stented with an acceptable in-stent restenosis rate. (Jpn Heart J 2003; 44: 163-177)

Effects of Angiotensin-Converting Enzyme Inhibitors or an Angiotensin Receptor Blocker in Combination With Aspirin and Cilostazol on In-stent Restenosis

“…We do not know whether and how our results may be modified if, for example, smaller vessels less than 2.8 mm in diameter, which have high rates of restenosis, are treated. 26) Fifth, we can not assess the possibility that patients who withdrew may have influenced the results if they had not been withdrawn. Sixth, an IVUS study 6 months after stent implantation may have been helpful to confirm whether the increased rate of target lesion revascularization in the ACE inhibitor group is due to intimal hyperplasia.…”